Strengthening health system's capacity for pre-exposure prophylaxis for adolescent girls and young women and adolescent boys and young men in South Africa (SHeS'Cap-PrEP): Protocol for a mixed methods study in KwaZulu-Natal, South Africa.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
02
2022
accepted:
03
03
2022
entrez:
17
3
2022
pubmed:
18
3
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Pre-exposure prophylaxis (PrEP) is an effective prevention intervention that can be used to control HIV incidence especially among people who are at increased risk for HIV such as adolescent girls and young women (AGYW) and adolescent boys and young men (ABYM). In South Africa, various approaches of delivering PrEP have been adopted at different service delivery points (facility-based only, school-based only, community-based only and hybrid school-facility and community-facility models) to overcome challenges associated with individual, structural, and health systems related barriers that may hinder access to and uptake of PrEP among these populations. However, little is known about how to optimize PrEP implementation and operational strategies to achieve high sustained uptake of good quality services for AGYW and ABYM. This study aims to identify effective and feasible PrEP models of care for improving PrEP uptake, continuation, and adherence among AGYW and ABYM. A sequential explanatory mixed-methods study will be conducted in 22 service delivery points (SDPs) in uMgungundlovu district, KwaZulu-Natal, South Africa. We will recruit 600 HIV negative, sexually active, high risk, AGYW (aged 15-24 years) and ABYM (aged 15-35 years). Enrolled participants will be followed up at 1-, 4- and 7-months to determine continuation and adherence to PrEP. We will conduct two focus group discussions (with 8 participants in each group) across four groups (i. Initiated PrEP within 1 month, ii. Did not initiate PrEP within 1 month, iii. Continued PrEP at 4/7 months and iv. Did not continue PrEP at 4/7 months) and 48 in-depth interviews from each of the four groups (12 per group). Twelve key informant interviews with stakeholders working in HIV programs will also be conducted. Associations between demographic characteristics stratified by PrEP initiation and by various service-delivery models will be assessed using Chi-square/Fishers exact tests or t-test/Mann Whitney test. A general inductive approach will be used to analyze the qualitative data. The protocol was approved by the South African Medical Research Council Health Research Ethics Committee (EC051-11/2020). Findings from the study will be communicated to the study population and results will be presented to stakeholders and at appropriate local and international conferences. Outputs will also include a policy brief, peer-reviewed journal articles and research capacity building through research degrees.
Identifiants
pubmed: 35298487
doi: 10.1371/journal.pone.0264808
pii: PONE-D-22-04537
pmc: PMC8929690
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0264808Subventions
Organisme : Medical Research Council
ID : MR/T040246/1
Pays : United Kingdom
Organisme : CDC HHS
ID : NU2GGH002093
Pays : United States
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: the authors declare no competing interest.
Références
PLoS Med. 2015 Nov 24;12(11):e1001906
pubmed: 26599825
Glob Health Action. 2021 Jan 1;14(1):1886455
pubmed: 33606603
Afr J AIDS Res. 2020 Mar;19(1):13-23
pubmed: 32174231
Soc Sci Med. 2008 May;66(10):2108-21
pubmed: 18329774
Pediatr Res. 2016 Jun;79(6):838-45
pubmed: 26882367
J Community Health. 2019 Dec;44(6):1150-1159
pubmed: 31280429
AIDS Behav. 2020 May;24(5):1342-1357
pubmed: 31776819
Medicine (Baltimore). 2019 Oct;98(43):e17716
pubmed: 31651904
Lancet. 2018 Dec 1;392(10162):2334-2335
pubmed: 30527600
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):313-322
pubmed: 27243900
BMC Womens Health. 2020 Jan 16;20(1):7
pubmed: 31948429
BMC Infect Dis. 2016 Jul 12;16 Suppl 2:315
pubmed: 27410689
PLoS One. 2017 Oct 12;12(10):e0186316
pubmed: 29023510
PLoS One. 2018 Apr 27;13(4):e0196280
pubmed: 29702659
Lancet HIV. 2020 Apr;7(4):e249-e261
pubmed: 32087152
Sex Health. 2018 Nov;15(6):513-521
pubmed: 30408431
PLoS One. 2018 Jul 19;13(7):e0199733
pubmed: 30024908
AIDS Patient Care STDS. 2016 Jun;30(6):274-81
pubmed: 27286296
J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):580-589
pubmed: 30239426
Lancet HIV. 2017 Jan;4(1):e41-e50
pubmed: 27914874
J Adolesc Health. 2017 Feb;60(2S2):S35-S44
pubmed: 28109339
BMC Public Health. 2020 Jan 15;20(1):69
pubmed: 31941469
Int J Health Policy Manag. 2021 Mar 01;10(3):129-140
pubmed: 32610748
J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):154-159
pubmed: 29076883